Search Results - Richards-Peterson, Lauren E.

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib

    Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib by Suttle, A. Benjamin, Grossmann, Kenneth F., Ouellet, Daniele, Richards-Peterson, Lauren E., Aktan, Gursel, Gordon, Michael S., LoRusso, Patricia M., Infante, Jeffrey R., Sharma, Sunil, Kendra, Kari, Patel, Manish, Pant, Shubham, Arkenau, Hendrik-Tobias, Middleton, Mark R., Blackman, Samuel C., Botbyl, Jeff, Carson, Stanley W.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors

    Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors by Denton, Cathrine L., Minthorn, Elisabeth, Carson, Stanley W., Young, Graeme C., Richards-Peterson, Lauren E., Botbyl, Jeffrey, Han, Chao, Morrison, Royce A., Blackman, Samuel C., Ouellet, Daniele

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites

    Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites by Ellens, Harma, Johnson, Marta, Lawrence, Sarah K., Watson, Cory, Chen, Liangfu, Richards-Peterson, Lauren E.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Abstract 3773: Absolute bioavailability of BRAF inhibitor GSK2118436: Use of a microtracer study in patients with cancer

    Abstract 3773: Absolute bioavailability of BRAF inhibitor GSK2118436: Use of a microtracer study in patients with cancer by Denton, Cathrine L., Carson, Stanley W., Young, Graeme C., Richards-Peterson, Lauren E., Botbyl, Jeffrey, Morrison, Royce A., Blackman, Samuel C., Ouellet, Daniele

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers

    Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers by Weisel, Kathleen, Scott, Nicola E., Tompson, Debra J., Votta, Bartholomew J., Madhavan, Sujith, Povey, Kat, Wolstenholme, Allen, Simeoni, Monica, Rudo, Todd, Richards‐Peterson, Lauren, Sahota, Tarjinder, Wang, J. Gene, Lich, John, Finger, Joshua, Verticelli, Adeline, Reilly, Michael, Gough, Peter J., Harris, Philip A., Bertin, John, Wang, Mei‐Lun

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK 1 inhibitor GSK 2982772 in healthy volunteers

    Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK 1 inhibitor GSK 2982772 in healthy volunteers by Weisel, Kathleen, Scott, Nicola E., Tompson, Debra J., Votta, Bartholomew J., Madhavan, Sujith, Povey, Kat, Wolstenholme, Allen, Simeoni, Monica, Rudo, Todd, Richards‐Peterson, Lauren, Sahota, Tarjinder, Wang, J. Gene, Lich, John, Finger, Joshua, Verticelli, Adeline, Reilly, Michael, Gough, Peter J., Harris, Philip A., Bertin, John, Wang, Mei‐Lun

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: